Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Recurrence risk high regardless of VTE classification

Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4

Key clinical point: Significant recurrence risk among all three classifications of VTE indicates a need to rethink how patients are categorized.

Major finding: At 10-year follow-up, recurrence rates per 100 person-years were 3.70 for patients with cancer-related VTE, 2.84 for patients with unprovoked VTE, and 2.22 for patients with provoked VTE.

Study details: An observational cohort study of 73,993 Danish patients with incident venous thromboembolism during January 2000–December 2015.

Disclosures: The study was partially funded by a grant from the Obel Family Foundation. Some authors reported financial disclosures related to Janssen, Bayer, Roche, and others.

Read the article here.

Citation:

Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4